The cure, or even just an effective treatment, for Alzheimer's disease has remained elusive for decades. Many pharmaceutical companies to date have jumped on the bandwagon for targeting beta amyloid plaques after they develop. Unfortunately, no matter how promising drugs appear in phase 2 results, they fail in phase 3 trials without slowing the progression of this debilitating neurological disease. Now, researchers at the University of Cambridge have discovered the mechanism for the formation of beta amyloid plaques. Can this discovery lead to an effective treatment? It certainly has potential, but developing antibodies to target the process will take many years. Get the details from Fool contributor Maxx Chatsko in the video below.
S&P 500
$5,958.38
+0.7%
+$41.45
DJI
$42,654.74
+0.8%
+$331.99
NASDAQ
$19,211.10
+0.5%
+$98.78
Bitcoin
$103,319.00
-0.2%
-$216.80
AAPL
$211.31
-0.1%
-$0.14
AMZN
$205.54
+0.2%
+$0.37
GOOG
$167.32
+1.2%
+$1.92
META
$640.11
-0.6%
-$3.77
MSFT
$453.88
+0.2%
+$0.75
NVDA
$135.20
+0.3%
+$0.38
TSLA
$349.44
+1.9%
+$6.62
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.